Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-01-11
2011-01-11
Swartz, Rodney P. (Department: 1645)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C424S009200, C424S130100, C424S134100, C424S171100, C424S184100, C424S193100, C435S004000, C435S174000, C436S501000, C436S518000
Reexamination Certificate
active
07867715
ABSTRACT:
The invention relates to an in vitro method of evaluating the immunological activity of a vaccine preparation in the form of a mixture of a molecular antigen and a carrier, wherein the mixture comprises a liquid phase and a solid phase, to which at least a part of the antigen is attached, the method comprising the steps ofi) subjecting the vaccine to one or more measurements;andii) using the measurement results to evaluate the immunological activity of the vaccine.
REFERENCES:
patent: 4127385 (1978-11-01), Weeke
patent: WO-9411734 (1994-05-01), None
patent: WO-9948525 (1999-09-01), None
patent: WO-0151926 (2001-07-01), None
patent: WO-2004038417 (2004-05-01), None
Katz, Jonathan B., et al., “In vitro assessment of viral antigen content in inactiviated aluminum hydroxide adjuvanted vaccines”, Journal of Virological Methods, 1989, vol. 25, No. 1, pp. 101-108.
Thraenhart, Olaf, et al., “Standardization of an enzyme immunoassay for the in vitro potency assay of inactivated tissue culture rabies vaccines: determination of the rabies virus glycoprotein with polyclonal antisera”, Journal of Biological Standardization (1989), vol. 17, No. 4, pp. 291-309.
Database WPI, Derwent Publications Ltd., XP002170319, AN 1993-212602, Jul. 7, 1992, Abstract.
Katz, J., “Desorption of Porcine Parvovirus from Aluminum Hydroxide Adjuvant with Subsequent Viral Immunoassay or Hemagglutination Assay”, Veterinary Research Communications, vol. 11, No. 1, 1987, pp. 83-92.
Lacey, C.J.N., et al., “Phase IIa Safety and Immunogenicity of a Therapeutic Vaccine, TA-GW, in Persons with Genital Warts”, Journal of Infectious Diseases, vol. 179, No. 3, Mar. 1999, pp. 612-618.
Krishnan, Lakshmi, et al., “Archaeosome Vaccine Adjuvants Induce Strong Humoral, Cell-Medicated, and Memory Responses: Comparison to Conventional Liposomes and Alum”, Infection and Immunity, vol. 68, No. 1, Jan. 2000, pp. 54-63.
Desbordes, J., “Problems Raised by Potincy Evaluation of Allergen Preparations”, Developments in Biological Standardization, vol. 29, 1975, pp. 219-226.
Hoffmann, A., et al., “Determination of the allergenic activity of birch pollen and apple prick test solutions by measurement of B-hexosaminidase release from RBL-2H3 cells. Comparison with classical methods in allergen standardization”, Allergy, vol. 54, No. 5, May 1999, pp. 446-454.
HogenEsch, Harm, et al., “Mechanisms of stimulation of the immune response by aluminum adjuvants”, Vaccine, vol. 20, May 31, 2002, pp. S34-S39.
Demoly, P., et al., “Allergen-induced mediator release tests”, Allergy, vol. 58, No. 7, Jul. 2003, pp. 553-558.
Levings, R.L., et a., “In vitro potency assays for nonreplicating veterinary vaccines: comparison to in vivo assays and considerations in assay development”, Veterinary Microbiology, vol. 37, No. 3-4, 1993, pp. 201-219.
Marsh et al., “Studies on ‘Allergoids’ Prepared from Naturally Occurring Allergens,” Immunology, 18, 705 (1970).
Wurtzen et al., “Chemical Modification of Birch Allergen Extract Leads to a Reduction in Allergenicity as well as Immunogenicity,” Int Arch Allergy Immunol, 144:287-295 (2007).
Gehlhar et al., “Characterization of Modified Allergen Extracts by in vitro B-Hexosaminidase Release from Rat Basophils,” Int Arch Allergy Immunol, 136:311-319 (2005).
Corbel et al., “Workshop on Standardisation of Aluminum Adsorbed Vaccines”, Biologicals (1997) 25, 351-353.
Yamamoto et al., “Quantitation of Group-specific α Antigen in Hepatitis B Vaccines by Anti-HBs/a Monoclonal Antibody”, Biologicals (1997) 25, 973-980.
Shi et al., “Detoxification of endotoxin by aluminum hydroxide adjuvant”, Vaccine 19 (2001) 1747-1752.
Maa et al., “Optimization of an Alum-Adsorbed Vaccine Powder Formulation for Epidermal Powder Immunization”, Pharmaceutical Research, vol. 20 (2003), No. 7: 969-977.
Shi et al., “Change in the degree of adsorption of proteins by aluminum-containing adjuvants following exposure to interstitial fluid: freshly prepared and aged model vaccines”, Vaccine 20 (2002) 80-85.
Geissler et al., “Quality Control and Stability of Chemically and Physically Modified Allergen Extracts”, Arbeiten aus der Paul-Ehrlich-Institut, 87:191-7 (1994).
Poulsen et al., “Aluminum Hydroxide Adsorbed Allergens Used in Modified RAST”, Allergy (1985), 40, 405-416.
Notice of Opposition to a European Patent; Patent No. 1649287; Opponent Novartis Vaccines & Diagnostics, Inc. (May 11, 2009)—14 pages.
Notice to opposition to a European Patent; Patent No. 1649287; Opponent Stallergenes S.A. (May 8, 2009)—42 pages (includes English translation).
Definition of alum adjuvant—National Cancer Institute Drug Dictionary.
Auszyme® FDA approval label (published Dec. 2001).
Reply of the Patent proprietor to the notice(s) of opposition to EP 1 649 287.
Ipsen Hans-Henrik
Jacobi Henrik H.
Lund Gitte
Würtzen Peter A
ALK-Abello A/S
Fish & Richardson P.C.
Swartz Rodney P.
LandOfFree
Method of evaluating the immunological activity of a vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of evaluating the immunological activity of a vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of evaluating the immunological activity of a vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2685629